Healthcare providers may consider: Bacterial culture if infection is suspected Temporary discontinuation of semaglutide to assess symptom resolution Referral to allergy/immunology for suspected hypersensitivity reactions For type 2 diabetes patients only, alternative GLP-1 receptor agonist formulations (such as oral semaglutide/Rybelsus) if injection site reactions are recurrent and problematic Patients with confirmed hypersensitivity to semaglutide should not continue the medication
Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity
Some patients experience reduced appetite to the point where eating feels less appealing, which, while therapeutically beneficial for weight management, can be disconcerting initially
Semaglutide and tirzepatide have different concentrations and different dose-to-volume ratios
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al
Leelakanok, N., Holcombe, A